Study Status: COMPLETED
Recruit Status: COMPLETED
Study Type: INTERVENTIONAL
Official Title: Improvement in Eczema and the Safety of Microbiome Baby Immunity Formula (SIM03) on Childhood Eczema Development - A Pilot Study
Brief Summary: Eczema is the most prevalent chronic skin disease in young children, and skin infection is commonly seen during eczema flare.
Dysbiosis is increasingly recognised in the stool and skin of these patients.
It is a common practice for parents to start these eczematous children on probiotics, but there is limited evidence if this treatment works in young patients.
This single-centre, open-label clinical trial aims to investigate the benefits of a 3-month treatment of young children with eczema with a new probiotics called microbiome baby immunity formula (SIM03).
Study outcomes include eczema severity, quality of life, biophysical measures of the skin and gastrointestinal symptoms, while adverse events related to this probiotics treatment will be monitored.
The effects of this intervention on stool microbiome will also be analysed.